Payment overview · 2025
General Payments
$816.06
40 reported records · 16 companies
Healthcare provider profile · identity verified
Ramesh Amara, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FRISCO, TX · NPI 1104892959
Verified facts
What the public records show
CMS Open Payments records show Ramesh Amara, MD received $816.06 in general payments during 2025 across 40 reported records.
Lilly USA, LLC accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGLYZA as an associated drug or biological on 111 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Onglyza by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $150.36 | 18.4% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $130.19 | 15.9% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $98.49 | 12.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.87 | 10.5% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $65.12 | 8.0% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $55.44 | 6.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.73 | 6.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.21 | 4.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.61 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.50 | 2.6% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $20.18 | 2.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.15 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.21 | 2.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.88 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.60 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.52 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $816.06 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $130.19 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $110.72 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $71.80 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $71.74 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $65.12 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $55.44 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.73 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.99 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | ONGLYZA open payments reported associated product |
CMS Open Payments — General Payments 111 supporting records · 89 recipient NPIs · example record 1206133840 |
Onglyza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 376 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 80 |
| Losartan Potassium | Losartan Potassium | 227 | 70 |
| Metformin Hcl | Metformin Hcl | 221 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 56 |
| Montelukast Sodium | Montelukast Sodium | 153 | 54 |
| Gabapentin | Gabapentin | 133 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 41 |
| Lisinopril | Lisinopril | 132 | 41 |
| Simvastatin | Simvastatin | 119 | 34 |
| Omeprazole | Omeprazole | 110 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 32 |
| Metformin Hcl Er | Metformin Hcl | 99 | 35 |
| Trazodone Hcl | Trazodone Hcl | 97 | 28 |
| Carvedilol | Carvedilol | 92 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 29 |
| Allopurinol | Allopurinol | 75 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 22 |
| Potassium Chloride | Potassium Chloride | 69 | 22 |
| Glimepiride | Glimepiride | 63 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 13 |
| Alendronate Sodium | Alendronate Sodium | 56 | 12 |
| Jardiance | Empagliflozin | 55 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 26 |
| Ozempic | Semaglutide | 53 | 13 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Furosemide | Furosemide | 48 | 17 |
| Januvia | Sitagliptin Phosphate | 47 | 11 |
| Ezetimibe | Ezetimibe | 46 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Glipizide Er | Glipizide | 44 | 13 |
| Synthroid | Levothyroxine Sodium | 41 | 12 |
| Famotidine | Famotidine | 38 | 13 |
| Sertraline Hcl | Sertraline Hcl | 38 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | 15 |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Atenolol | Atenolol | 32 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 11 |
| Glipizide | Glipizide | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Primidone | Primidone | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 16 |
| Trulicity | Dulaglutide | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Exforge | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Onglyza | Saxagliptin Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $816.06 · 40 records | Lilly USA, LLC | CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, Heplisav-B, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, OFEV, OTEZLA, Ozempic, REPATHA, SPRAVATO, TZIELD, UBRELVY, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error